Newest studies

Drug Repositioning: A Monetary Stratagem to Discover a New Application of Drugs

43/100 ✓ Peer-reviewed Drug development Current drug discovery technologies

Key finding: The choice of the methodology of drug repurposing relies on the accessible information about the drug molecule and like pharmacokinetic, pharmacological, physicochemical, and toxicological profile of the drug. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Generating new drug repurposing hypotheses using disease-specific hypergraphs

43/100 ✓ Peer-reviewed Drug development Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing

Key finding: We use a modified node2vec algorithm to generate pathway embeddings. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review

43/100 ✓ Peer-reviewed Treatments CNS & neurological disorders drug targets

Key finding: TTSs present some limit factors in terms of absorption due to skin physiology and the size of the molecules with established limits of percutaneous penetration (molecular mass of 500 g/mol and log P of 5). +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease

43/100 ✓ Peer-reviewed Drug development Journal of Alzheimer's disease : JAD

Key finding: Alzheimer's disease is a devastating neurodegenerative condition that exerts a significant global burden. +1 more finding

• Treatments
• Risk Factors

Full summary, score breakdown and related studies → Original source

Assays for the Screening and Characterization of Tau Aggregation Inhibitors

43/100 ✓ Peer-reviewed Drug development Methods in molecular biology (Clifton, N.J.)

Key finding: Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. +2 more findings

• Brain Biology

Full summary, score breakdown and related studies → Original source

Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies

54/100 ✓ Peer-reviewed Drug development The journal of prevention of Alzheimer's disease

Key finding: Serum concentrations of semorinemab were consistent across studies and showed a dose-proportional increase across the evaluated dose range. +4 more findings

• Clinical Trials

Full summary, score breakdown and related studies → Original source

At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact

77/100 ✓ Peer-reviewed Treatments The journal of prevention of Alzheimer's disease

Key finding: The overall number of participants enrolled was 192, with a mean (standard deviation) amyloid PET load at baseline of 101.80 (29.80) centiloids. +4 more findings

• Treatments
• Caregiving
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives

43/100 ✓ Peer-reviewed Treatments Chemical & pharmaceutical bulletin

Key finding: In this review, we provide updates on the results of clinical trials of anti-Aβ antibodies and anti-tau therapeutics and suggest future directions for these therapeutics.

• Treatments
• Clinical Trials
• Brain Biology

Full summary, score breakdown and related studies → Original source

Beyond Vision: A View from Eye to Alzheimer's Disease and Dementia

43/100 ✓ Peer-reviewed Brain scans and imaging The journal of prevention of Alzheimer's disease

Key finding: Growing epidemiologic evidence also suggests that eye disorders, such as cataracts, age-related macular degeneration, glaucoma, diabetic retinopathy, and so on, are closely associated with and even have a higher incidence of AD and dementia.

• Risk Factors

Full summary, score breakdown and related studies → Original source

Hyperspectral Retinal Imaging as a Non-Invasive Marker to Determine Brain Amyloid Status

43/100 ✓ Peer-reviewed Brain scans and imaging Journal of Alzheimer's disease : JAD

Key finding: The retinal reflectance spectra in the 450-585 nm wavelengths exhibited a significant difference in individuals with increasing brain amyloid. +4 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Amyloid PET Imaging: Standard Procedures and Semiquantification

43/100 ✓ Peer-reviewed Brain scans and imaging Methods in molecular biology (Clifton, N.J.)

Key finding: Amyloid plaques are a neuropathologic hallmark of Alzheimer's disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). +3 more findings

• Brain Scans
• Brain Biology

Full summary, score breakdown and related studies → Original source

Single Cell Sequencing Technology and Its Application in Alzheimer's Disease

43/100 ✓ Peer-reviewed Genetics Journal of Alzheimer's disease : JAD

Key finding: In recent years, high-throughput sequencing technologies have exhibited advantages in exploring the pathogenesis of diseases. +4 more findings

• Digital Tools

Full summary, score breakdown and related studies → Original source

Different Splice Isoforms of Peripheral Triggering Receptor Expressed on Myeloid Cells 2 mRNA Expressions are Associated With Cognitive Decline in Mild Dementia Due to Alzheimer's Disease and Reflect Central Neuroinflammation

43/100 ✓ Peer-reviewed TREM2 and immune genetics American journal of Alzheimer's disease and other dementias

Key finding: The results showed that increased TREM2 and TREM2alt mRNA expression is associated with AD pathogenesis at the mild dementia stage, thereby serving as a potential biomarker for early symptomatic stage of AD.

• Brain Biology

Full summary, score breakdown and related studies → Original source

A genome-wide association study of longitudinal change in CSF tau among non-demented elderly

59/100 ✓ Peer-reviewed Genetics Bratislavske lekarske listy

Key finding: The GWAS identified a significant single nucleotide polymorphism (SNP), rs17149074, within the C9orf171 (CFAP77) gene region that showed significant association with changes in CSF t-tau over time. +3 more findings

• Genetics
• Biomarkers

Full summary, score breakdown and related studies → Original source

Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia

43/100 ✓ Peer-reviewed Genetics Journal of Alzheimer's disease : JAD

Key finding: The molecules released into CSF, namely APOE2 for any dementia, APOE2 and Siglec-3 for AD, APOE2 for vascular dementia, and APOE2 for DLB, might be potential biomarkers. +2 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Impact of apolipoprotein E isoforms on sporadic Alzheimer's disease: beyond the role of amyloid beta

43/100 ✓ Peer-reviewed Genetics Neural regeneration research

Key finding: Consistent with the biological function of ApoE, ApoE4 isoform significantly altered signaling pathways associated with cholesterol homeostasis, transport, and myelination.

• Genetics
• Brain Biology
• Treatments

Full summary, score breakdown and related studies → Original source

[Efficiency of computerized cognitive training for prevention of cognitive impairments and stimulation of neuroplasticity.]

43/100 ✓ Peer-reviewed Cognitive tests and assessment Advances in gerontology = Uspekhi gerontologii

Key finding: Computerized cognitive training (CCT) is a rapidly developing area of cognitive rehabilitation at the intersection of information technology and healthcare, the constantly updated results of which can be successfully translated into practical application in clinical medicine and in particular in gerontology.

• Digital Tools
• Prevention
• Lifestyle

Full summary, score breakdown and related studies → Original source

Multidomain Dementia Risk Reduction in Primary Care is Feasible: A Proof-of-concept study

84/100 ✓ Peer-reviewed Cognitive tests and assessment Journal of Alzheimer's disease : JAD

Key finding: The interventions were positively perceived, with 72.0% finding the consultation informative and 69.2% considering the app useful. +4 more findings

• Clinical Trials
• Risk Factors
• Prevention

Full summary, score breakdown and related studies → Original source

Assessment of Mild Cognitive Impairment Using CogEvo: A Computerized Cognitive Function Assessment Tool

59/100 ✓ Peer-reviewed Cognitive tests and assessment Journal of primary care & community health

Key finding: Both total CogEvo and MMSE scores significantly decreased with age. +4 more findings

Full summary, score breakdown and related studies → Original source

Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings

43/100 ✓ Peer-reviewed Cognitive tests and assessment Methods in molecular biology (Clifton, N.J.)

Key finding: These methods involve analyzing cerebrospinal fluid and using positron emission tomography to accurately assess the presence of Aβ and tau proteins. +4 more findings

• Biomarkers
• Diagnosis
• Brain Biology

Full summary, score breakdown and related studies → Original source

Speech-Based Digital Biomarkers for Alzheimer's Research

43/100 ✓ Peer-reviewed Cognitive tests and assessment Methods in molecular biology (Clifton, N.J.)

Key finding: The aim of this chapter is to describe the methods that are needed to create speech collection scenarios that result in valuable speech-based digital biomarkers for clinical research.

• Biomarkers
• Digital Tools

Full summary, score breakdown and related studies → Original source

cCOG Web-Based Cognitive Assessment Tool

43/100 ✓ Peer-reviewed Cognitive tests and assessment Methods in molecular biology (Clifton, N.J.)

Key finding: Cognitive testing is an essential part of clinical diagnostics and clinical trials in Alzheimer's disease. +2 more findings

• Diagnosis

Full summary, score breakdown and related studies → Original source

Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Results in Patients with Suspected Alzheimer's Disease

54/100 ✓ Peer-reviewed Tau biomarkers Journal of Alzheimer's disease : JAD

Key finding: Comparing the discordant CSF results of each patient with the cerebral amyloid-PET results, we found that in the group with Aβ1 - 42+ and p-tau-CSF values, the amyloid-PET was positive in 51.2% and negative in 48.8% of patients, while in the group with Aβ1 - 42-and p-Tau+ CSF values, the amyloid-PET was positive in 52.6% of patients and negative in 47.4% of them. +3 more findings

• Biomarkers
• Brain Scans

Full summary, score breakdown and related studies → Original source

Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults

59/100 ✓ Peer-reviewed Biomarkers The journal of prevention of Alzheimer's disease

Key finding: Six miRNAs (hsa-miR-128-3p, hsa-miR-144-5p, hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-29c-3p and hsa-miR-363-3p) were downregulated in the blood of individuals with low cognitive performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

A Decade of Protecting Progress: Ethics Review

43/100 ✓ Peer-reviewed Biomarkers Journal of Alzheimer's disease : JAD

Key finding: At the same time, people living with and at risk for dementia want access to their test results and involvement in their care.

Full summary, score breakdown and related studies → Original source